Lack of Survival Benefit Following Liver Transplantation with MELD Exception Points for Hepatocellular Carcinoma: Beyond the Unblinding of Lady Justice

Gastroenterology

Volumn 149, Issue 3, 2015, Pages 531-534

  Ghabril, Marwan ^a   Charlton, Michael ^b  

^a INDIANA UNIVERSITY   (United States)

^b INTERMOUNTAIN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BILIRUBIN; CREATININE;

ALPHA FETOPROTEIN BLOOD LEVEL; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CHILD TURCOTTE PUGH SCORE; HOSPITAL ADMISSION; HUMAN; JUSTICE; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MODEL FOR END STAGE LIVER DISEASE SCORE; PRIORITY JOURNAL; PROTHROMBIN TIME; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; CARCINOMA, HEPATOCELLULAR; DECISION SUPPORT SYSTEM; FEMALE; LIVER NEOPLASMS; MALE;

CARCINOMA, HEPATOCELLULAR; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE;

EID: 84939789734     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.07.028     Document Type: Editorial

References (19)

1. United Network for Organ Sharing (UNOS). [Homepage on the Internet]. Available from: www.UNOS.org
2. A.B. Massie, E.K. Chow, C.E. Wickliffe, and et al. Early changes in liver distribution following implementation of Share 35 Am J Transplant 15 2015 659 667
3. M. Malinchoc, P.S. Kamath, F.D. Gordon, and et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts [see comments] Hepatology 31 4 2000 864 871
4. R.H. Wiesner, S.V. McDiarmid, P.S. Kamath, and et al. MELD and PELD: application of survival models to liver allocation Liver Transpl 7 7 2001 567 580
5. R.B. Freeman, R.H. Wiesner, E. Edwards, and et al. Results of the first year of the new liver allocation plan Liver Transpl 10 1 2004 7 15
6. P.G. Northup, N.M. Intagliata, N.L. Shah, and et al. Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation Hepatology 61 1 2015 285 291
7. G.N. Ioannou, J.D. Perkins, and R.L. Carithers Jr. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival Gastroenterology 134 5 2008 1342 1351
8. E.A. Pomfret, K. Washburn, C. Wald, and et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States Liver Transpl 16 3 2010 262 278
9. A.B. Massie, B. Caffo, S.E. Gentry, and et al. MELD Exceptions and Rates of Waiting List Outcomes Am J Transplant 11 11 2011 2362 2371
10. K. Washburn, E. Edwards, A. Harper, and et al. Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system Am J Transplant 10 7 2010 1643 1648
11. D. Goldberg, B. French, P. Abt, and et al. Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma Liver Transpl 18 4 2012 434 443
12. K. Berry, and G.N. Ioannou Comparison of liver transplant-related survival benefit in patients with vs without hepatocellular carcinoma in the United States Gastroenterology 149 2015 669 680
13. C. Toso, E. Dupuis-Lozeron, P. Majno, and et al. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list Hepatology 56 1 2012 149 156
14. P.R. Salvalaggio, G. Felga, D.A. Axelrod, and et al. List and liver transplant survival according to waiting time in patients with hepatocellular carcinoma Am J Transplant 15 3 2015 668 677
15. M.L. Samoylova, J.L. Dodge, F.Y. Yao, and et al. Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation Liver Transpl 20 8 2014 937 944
16. B. Schlansky, Y. Chen, D.L. Scott, and et al. Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry Liver Transpl 20 9 2014 1045 1056
17. J.K. Heimbach, R. Hirose, P.G. Stock, and et al. Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States Hepatology 61 5 2015 1643 1650
18. M.R. Marvin, N. Ferguson, R.M. Cannon, and et al. MELDEQ: an alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma Liver Transpl 21 5 2015 612 622
19. A. Vitale, M.L. Volk, T.M. De Feo, and et al. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list J Hepatol 60 2 2014 290 297